NEW YORK, NY / ACCESSWIRE / March 17, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Geron Corporation (NASDAQ:GERN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/geron-corporation-et-al-loss-submission-form?prid=5716&wire=1
Lead Plaintiff Deadline: March 23, 2020
Class Period: March 19, 2018 to September 26, 2018
The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.
Tivity Health, Inc. (NASDAQ:TVTY)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/tivity-health-inc-loss-submission-form?prid=5716&wire=1
Lead Plaintiff Deadline: April 27, 2020
Class Period: March 8, 2019 to February 19, 2020
Allegations against TVTY include that: (i) following the Nutrisystem Acquisition, Tivity's Nutrition segment faced significant operational challenges; (ii) the foregoing would foreseeably have a significant impact on Tivity's revenues; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Cronos Group Inc. (NASDAQ:CRON)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/cronos-group-inc-loss-submission-form-2?prid=5716&wire=1
Lead Plaintiff Deadline: May 11, 2020
Class Period: May 9, 2019 to March 2, 2020
Allegations against CRON include that: (i) Cronos had engaged in significant transactions for which its revenue recognition was inappropriate; (ii) the foregoing would foreseeably necessitate reviews that would delay the Company's ability to timely file its periodic reports; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong